Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Liposomal Doxorubicin (Caelyx) + Trastuzumab + Docetaxel as First-line Therapy in HER2-positive Metastatic Breast Cancer
2004-003989-15Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Merck & Co. Primary endpoints: Determination of safest Caelyx dose in combination regimen and Tumor response rate. Started Nov 2008; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2004-003989-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003989-15.